LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

19.54 -1.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.39

Massimo

19.76

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+105.06% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-77M 1.8B
Apertura precedente	20.6
Chiusura precedente	19.54

Notizie sul Sentiment di mercato

By Acuity

50%

156 / 344 Classifica in Healthcare

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 mag 2026, 22:47 UTC

Utili

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mag 2026, 20:45 UTC

Utili

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mag 2026, 23:31 UTC

Discorsi di Mercato

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mag 2026, 23:17 UTC

Discorsi di Mercato

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mag 2026, 23:02 UTC

Discorsi di Mercato

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mag 2026, 22:37 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mag 2026, 21:12 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mag 2026, 21:00 UTC

Utili

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mag 2026, 20:57 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:55 UTC

Utili

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

28 mag 2026, 20:48 UTC

Azioni calde

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mag 2026, 20:34 UTC

Utili

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mag 2026, 20:31 UTC

Utili

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mag 2026, 20:28 UTC

Utili

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mag 2026, 20:26 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Membership Fees $1.37B

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Net Sales $69.15B

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Same-Store Sales Up 9.8% >COST

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

105.06% in crescita

Previsioni per 12 mesi

Media 40.5 USD 105.06%

Alto 57 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

156 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.